TW202019905A - 異喹啉化合物及其用途 - Google Patents
異喹啉化合物及其用途 Download PDFInfo
- Publication number
- TW202019905A TW202019905A TW108126067A TW108126067A TW202019905A TW 202019905 A TW202019905 A TW 202019905A TW 108126067 A TW108126067 A TW 108126067A TW 108126067 A TW108126067 A TW 108126067A TW 202019905 A TW202019905 A TW 202019905A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- group
- aryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
- 0 *c1c(*)c(cc(N*)nc2)c2c(*)c1* Chemical compound *c1c(*)c(cc(N*)nc2)c2c(*)c1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018096780 | 2018-07-24 | ||
| WOPCT/CN2018/096780 | 2018-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202019905A true TW202019905A (zh) | 2020-06-01 |
Family
ID=67551418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108126067A TW202019905A (zh) | 2018-07-24 | 2019-07-23 | 異喹啉化合物及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12378249B2 (enExample) |
| EP (1) | EP3826722B1 (enExample) |
| JP (1) | JP7386841B2 (enExample) |
| CN (1) | CN112601584A (enExample) |
| TW (1) | TW202019905A (enExample) |
| WO (1) | WO2020023560A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019010302A (es) | 2017-03-30 | 2019-11-21 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1. |
| JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
| WO2020069402A1 (en) * | 2018-09-30 | 2020-04-02 | Genentech, Inc. | Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| TW202023558A (zh) | 2018-10-03 | 2020-07-01 | 美商建南德克公司 | 8-胺基異喹啉化合物及其用途 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| EP4090663A1 (en) * | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| CN116456985A (zh) * | 2020-09-23 | 2023-07-18 | 深圳市原力生命科学有限公司 | 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法 |
| EP4240361A4 (en) * | 2020-11-09 | 2024-09-25 | Merck Sharp & Dohme LLC | INHIBITORS, OF THE 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE TYPE, OF HPK1 |
| CN114516857A (zh) * | 2020-11-20 | 2022-05-20 | 深圳智药信息科技有限公司 | Hpk1抑制剂及其用途 |
| US20240182465A1 (en) * | 2021-03-03 | 2024-06-06 | Genfleet Therapeutics (Shanghai) Inc. | Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof |
| WO2023001794A1 (en) | 2021-07-20 | 2023-01-26 | Astrazeneca Ab | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
| US20250084078A1 (en) * | 2022-01-04 | 2025-03-13 | Genfleft Therapeutics (Shanghai) Inc. | Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof |
| CN116672450A (zh) * | 2022-02-23 | 2023-09-01 | 智宠制药（北京）有限公司 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| CN119790047A (zh) * | 2022-09-22 | 2025-04-08 | 北京望实智慧科技有限公司 | Hpk1抑制剂、制备方法及其用途 |
| WO2025029995A1 (en) * | 2023-08-01 | 2025-02-06 | Arvinas Operations, Inc. | Hpk1 targeting compounds and uses thereof |
| CN117229202B (zh) * | 2023-11-15 | 2024-01-26 | 苏州美诺医药科技有限公司 | 一种brd9靶向降解化合物的中间体的制备方法 |
| WO2026035878A1 (en) * | 2024-08-07 | 2026-02-12 | Nimbus Saturn, Inc. | Hpk1 inhibitor formulations and methods of making the same |
| WO2026035872A1 (en) * | 2024-08-07 | 2026-02-12 | Nimbus Saturn, Inc. | Hpk1 inhibitor formulations and methods of making the same |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE3034001A1 (de) | 1980-09-10 | 1982-04-22 | Hoechst Ag, 6000 Frankfurt | Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung |
| PL176081B1 (pl) | 1995-06-06 | 1999-04-30 | Politechnika Warszawska | Sposób wytwarzania 3-aminoizochinoliny i jej N-mono oraz N,N-dipodstawionych pochodnych |
| WO2000071511A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US7199149B2 (en) | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
| JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US20060156485A1 (en) | 2005-01-14 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| EP1899322B1 (en) | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| DOP2006000233A (es) | 2005-10-28 | 2007-06-15 | Lilly Co Eli | Inhibidores de cinasa |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| AU2007207743B2 (en) | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| WO2007125405A2 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| AU2007338410B2 (en) | 2006-12-27 | 2012-08-16 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| EP1975166A1 (en) | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
| EP2008658A1 (en) | 2007-06-28 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives |
| CN101821279A (zh) | 2007-08-15 | 2010-09-01 | 赛特凯恩蒂克公司 | 某些化学个体、组合物和方法 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| JP5793766B2 (ja) | 2009-12-16 | 2015-10-14 | ファイザー・インク | 抗菌剤として有用なｎ−結合型ヒドロキサム酸誘導体 |
| CN102791687B (zh) | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| EP2552893B1 (en) | 2010-03-31 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Antibacterial isoquinolin-3-ylurea derivatives |
| CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| CA2817460A1 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| WO2012137099A1 (en) | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| JP2014523880A (ja) | 2011-06-23 | 2014-09-18 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 金属酵素化合物 |
| WO2013003315A2 (en) | 2011-06-26 | 2013-01-03 | President And Fellows Of Harvard College | Methods for preparing isoquinolines |
| WO2013169793A2 (en) | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
| CA2882750A1 (en) | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
| GB201216018D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| CA2883386A1 (en) | 2012-09-14 | 2014-03-20 | Eternity Bioscience Inc. | Aminoisoquinoline derivatives as protein kinase inhibitors |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| JP6397010B2 (ja) | 2013-07-03 | 2018-09-26 | カリオファーム セラピューティクス，インコーポレイテッド | 置換されたベンゾフラニル及びベンゾオキサゾリル化合物並びにその使用 |
| WO2016014674A1 (en) | 2014-07-22 | 2016-01-28 | University Of Maryland, College Park | Linked diaryl compounds with anticancer properties and methods of using the same |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| RS61919B1 (sr) * | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibitori hpk1 i postupci za njihovo korišćenje |
| AU2016340798A1 (en) | 2015-10-20 | 2018-04-26 | Axovant Sciences Gmbh | Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors |
| BR112017002594A2 (pt) | 2015-12-17 | 2017-12-19 | Gilead Sciences Inc | compostos inibidores de cinase de ligação de tank |
| CN107163022B (zh) | 2016-03-07 | 2021-07-16 | 上海如絮生物科技有限公司 | 一种异喹啉类化合物、其中间体、制备方法和应用 |
| US10407421B2 (en) | 2016-03-07 | 2019-09-10 | Merck Sharp & Dohme Corp | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN107266421B (zh) | 2016-04-08 | 2020-12-04 | 正大天晴药业集团股份有限公司 | 取代的苯并咪唑类衍生物 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| US10280164B2 (en) * | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| AR109596A1 (es) * | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US11180482B2 (en) * | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| MX2019010302A (es) * | 2017-03-30 | 2019-11-21 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1. |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| AR111307A1 (es) | 2017-03-30 | 2019-06-26 | Takeda Pharmaceuticals Co | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa |
| CN110831593A (zh) | 2017-06-14 | 2020-02-21 | 特维娜有限公司 | 用于调节s1p1活性的化合物及其使用方法 |
| US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
| US10653688B2 (en) | 2017-10-27 | 2020-05-19 | Samumed, Llc | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
| US20210009541A1 (en) | 2018-02-12 | 2021-01-14 | Bayer Aktiengesellschaft | Fungicidal oxadiazoles |
| JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| TW202023558A (zh) | 2018-10-03 | 2020-07-01 | 美商建南德克公司 | 8-胺基異喹啉化合物及其用途 |
-
2019
- 2019-07-23 JP JP2021503147A patent/JP7386841B2/ja active Active
- 2019-07-23 CN CN201980055319.5A patent/CN112601584A/zh active Pending
- 2019-07-23 TW TW108126067A patent/TW202019905A/zh unknown
- 2019-07-23 WO PCT/US2019/043123 patent/WO2020023560A1/en not_active Ceased
- 2019-07-23 EP EP19750199.2A patent/EP3826722B1/en active Active
-
2021
- 2021-01-22 US US17/156,387 patent/US12378249B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3826722C0 (en) | 2026-02-18 |
| JP2021532109A (ja) | 2021-11-25 |
| CN112601584A (zh) | 2021-04-02 |
| US12378249B2 (en) | 2025-08-05 |
| EP3826722B1 (en) | 2026-02-18 |
| US20210253580A1 (en) | 2021-08-19 |
| WO2020023560A1 (en) | 2020-01-30 |
| JP7386841B2 (ja) | 2023-11-27 |
| EP3826722A1 (en) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12378249B2 (en) | Isoquinoline compounds and uses thereof | |
| US11034692B1 (en) | Naphthyridines as inhibitors of HPK1 | |
| US11566003B2 (en) | Isoquinolines as inhibitors of HPK1 | |
| JP7386842B2 (ja) | ナフチリジン化合物およびその使用 | |
| CN110402248B (zh) | 作为hpk1抑制剂的氮杂吲哚类 | |
| JP7482118B2 (ja) | 癌の治療用のイソキノリン化合物 | |
| US12208088B2 (en) | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | |
| US20240368170A1 (en) | Cinnoline compounds and uses thereof | |
| HK40043202A (en) | Isoquinoline compounds and uses thereof | |
| HK40042235A (en) | Naphthyridine compounds and uses thereof |